No Data
CRYOFOCUS-B: ANNUAL REPORT 2024
Kangfeng Biotech-B (06922) announced its 2024 annual performance, with a loss attributable to Shareholders of 0.104 billion yuan, an increase of 7.1% year-on-year.
Kangfeng Biological-B (06922) released its performance for the year 2024, with revenue of 53.531 million yuan (RMB, the same below)...
Express News | Cryofocus Medtech Shanghai FY Revenue RMB 53.5 Million
CRYOFOCUS-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024
Kangfeng Bio-B (06922.HK) plans to hold a Board of Directors meeting on March 31 to approve the annual performance.
Glory Holdings announced on March 19 that Kangfeng Bio-B (06922.HK) has scheduled a Board of Directors meeting on March 31, 2025 (Monday) to review and approve the group's annual performance for the year ended December 31, 2024, and its release, as well as to review the proposal for the distribution of a final dividend (if any).
Kangfeng Biotechnology-B (06922.HK): The malignant stenosis cryoablation system has obtained approval from the National Medical Products Administration.
Gelonghui, March 6th丨Kangfeng Biological-B (06922.HK) announced that on March 6, 2025, the group’s malignant stenosis cryoablation system, which is one of the group’s respiratory intervention products, consisting of cryotherapy equipment and airway cryoablation catheters, has obtained the approval from the National Medical Products Administration. The malignant stenosis cryoablation system is an independently developed cryoablation system used for ablating malignant airway tumor tissues and reducing the frequency of airway restenosis. During the surgical procedure, the malignant stenosis cryoablation system utilizes the ultra-low temperature generated by the cryoablation system to ablate tumor cells in the tracheal lumen and wall, and then proceed with reheating.
